These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 32515665)

  • 1. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 5. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    van Vollenhoven RF; Hall S; Wells AF; Meerwein S; Song Y; Tanjinatus O; Fleischmann R
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upadacitinib tartrate in rheumatoid arthritis.
    Stamatis P; Bogdanos DP; Sakkas LI
    Drugs Today (Barc); 2020 Nov; 56(11):723-732. PubMed ID: 33332480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
    Boyce EG; Rogan EL; C Lui M
    Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
    Conaghan PG; Mysler E; Tanaka Y; Da Silva-Tillmann B; Shaw T; Liu J; Ferguson R; Enejosa JV; Cohen S; Nash P; Rigby W; Burmester G
    Drug Saf; 2021 May; 44(5):515-530. PubMed ID: 33527177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication.
    Mohamed MF; Klünder B; Othman AA
    Clin Pharmacokinet; 2020 May; 59(5):531-544. PubMed ID: 31867699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
    Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.